Pliant Therapeutics, Inc.
PLRX
$1.48
$0.010.68%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | 0.00 | 0.00 | 248.00K | 1.58M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 0.00 | 0.00 | 248.00K | 1.58M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | 0.00 | 0.00 | 248.00K | 1.58M |
| SG&A Expenses | 59.06M | 58.38M | 59.47M | 59.02M | 57.93M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 228.37M | 222.08M | 207.75M | 194.69M | 185.73M |
| Operating Income | -228.37M | -222.08M | -207.75M | -194.44M | -184.15M |
| Income Before Tax | -210.30M | -201.68M | -185.41M | -170.74M | -161.34M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -210.30 | -201.68 | -185.41 | -170.74 | -161.34 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -210.30M | -201.68M | -185.41M | -170.74M | -161.34M |
| EBIT | -228.37M | -222.08M | -207.75M | -194.44M | -184.15M |
| EBITDA | -226.24M | -219.95M | -205.71M | -192.54M | -182.30M |
| EPS Basic | -3.47 | -3.34 | -3.09 | -2.86 | -2.75 |
| Normalized Basic EPS | -2.17 | -2.09 | -1.93 | -1.79 | -1.72 |
| EPS Diluted | -3.47 | -3.34 | -3.09 | -2.86 | -2.75 |
| Normalized Diluted EPS | -2.17 | -2.09 | -1.93 | -1.79 | -1.72 |
| Average Basic Shares Outstanding | 242.15M | 241.20M | 240.16M | 238.95M | 234.82M |
| Average Diluted Shares Outstanding | 242.15M | 241.20M | 240.16M | 238.95M | 234.82M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |